Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2020-04-28 Interim / Quarterly Rep…
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Quarterly Report and Appendix 4C 7 pages 224.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "Quarterly report for the period ending 31 March 2020" and includes detailed financial data such as consolidated statements of cash flows, cash equivalents, financing facilities, and operational updates. It references compliance with ASX Listing Rule 4.7B, which pertains to quarterly cash flow reporting. The document contains substantive financial data and analysis for a period shorter than a full fiscal year (a quarter). It is not merely an announcement or a certification but a comprehensive financial report for the quarter. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2020
2020-04-28 English
Continued Suspension 1 page 116.0KB
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the Australian Securities Exchange requesting a voluntary suspension of trading in the company's securities. It references ASX Listing Rule 17.2 and states the company is seeking suspension pending a response to a price query. There is no financial data, report, or detailed analysis present. The document is a regulatory announcement related to trading status rather than a financial report or management information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-04-27 English
Continued Suspension 1 page 93.8KB
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to the Australian Securities Exchange requesting a voluntary suspension of trading in the company's securities. It references ASX Listing Rule 17.2 and explains the reason for the suspension request related to a price query. The document is short (1175 characters) and is an announcement of a trading suspension, not a financial report or detailed filing. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like financial reports, management changes, or capital updates.
2020-04-19 English
Suspension from Official Quotation 2 pages 189.5KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Neurotech International Limited regarding a voluntary suspension of its securities from official quotation on the ASX. It references ASX Listing Rule 17.2 and details the request for suspension pending a response to a price query. The document is short (1866 characters) and is an official notice about trading suspension, not a financial report or detailed filing. It does not contain financial data, management discussion, or audit information. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2020-04-13 English
Mente receives CE Mark renewal for use with ASD Children 2 pages 170.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX release dated 9 April 2020 announcing the renewal of the CE Mark for Neurotech International's medical device Mente, used for therapy in children with autism spectrum disorder (ASD). The content focuses on the product certification, company milestones, and general company information. There are no financial statements, earnings data, management discussion, or regulatory filings related to financial performance. The document is relatively short (3526 characters) and serves as a corporate announcement about a product certification milestone rather than a financial or regulatory report. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2020-04-08 English
Becoming a substantial holder x4 8 pages 6.0MB
Major Shareholding Notification Classification · 100% confidence The document is a "Notice of initial substantial holder" filed under the Corporations Act 2001 Section 671B. It details the substantial shareholdings of entities in Neurotech International Limited, including voting power, relevant interests, registered holders, and consideration paid. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category of Major Shareholding Notification (MRQ). The document is not an annual report, earnings release, or any other financial report but a regulatory disclosure of shareholding changes.
2020-04-08 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.